Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective: To test the hypothesis that systemic and inhaled glucocorticoid use is associated with changes in grey matter volume (GMV) and white matter microstructure. Design: Cross-sectional study. Setting: UK Biobank, a prospective population-based cohort study of adults recruited in the UK between 2006 and 2010. Participants: After exclusion based on neurological, psychiatric or endocrinological history, and use of psychotropic medication, 222 systemic glucocorticoid users, 557 inhaled glucocorticoid users and 24 106 controls with available T1 and diffusion MRI data were included. Main outcome measures: Primary outcomes were differences in 22 volumetric and 14 diffusion imaging parameters between glucocorticoid users and controls, determined using linear regression analyses adjusted for potential confounders. Secondary outcomes included cognitive functioning (six tests) and emotional symptoms (four questions). Results: Both systemic and inhaled glucocorticoid use were associated with reduced white matter integrity (lower fractional anisotropy (FA) and higher mean diffusivity (MD)) compared with controls, with larger effect sizes in systemic users (FA: adjusted mean difference (AMD)=−3.7e-3, 95% CI=−6.4e-3 to 1.0e-3; MD: AMD=7.2e-6, 95% CI=3.2e-6 to 1.1e-5) than inhaled users (FA: AMD=−2.3e-3, 95% CI=−4.0e-3 to −5.7e-4; MD: AMD=2.7e-6, 95% CI=1.7e-7 to 5.2e-6). Systemic use was also associated with larger caudate GMV (AMD=178.7 mm 3 , 95% CI=82.2 to 275.0), while inhaled users had smaller amygdala GMV (AMD=−23.9 mm 3 , 95% CI=−41.5 to −6.2) than controls. As for secondary outcomes, systemic users performed worse on the symbol digit substitution task (AMD=−0.17 SD, 95% CI=−0.34 to −0.01), and reported more depressive symptoms (OR=1.76, 95% CI=1.25 to 2.43), disinterest (OR=1.84, 95% CI=1.29 to 2.56), tenseness/restlessness (OR=1.78, 95% CI=1.29 to 2.41), and tiredness/lethargy (OR=1.90, 95% CI=1.45 to 2.50) compared with controls. Inhaled users only reported more tiredness/lethargy (OR=1.35, 95% CI=1.14 to 1.60). Conclusions: Both systemic and inhaled glucocorticoid use are associated with decreased white matter integrity and limited changes in GMV. This association may contribute to the neuropsychiatric side effects of glucocorticoid medication, especially with chronic use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies on chronic corticosteroid use have revealed correlations between corticosteroid dose and regimen and the extent of alterations in brain volume and white matter microstructure (Van Der Meulen et al., 2022; Geuens et al., 2023).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Van Der Meulen et al., 2022
In the citing paper
“Chronic corticosteroid treatment exacerbates grey matter volume reductions (Geuens et al., 2023), white matter alterations (Van Der Meulen et al., 2022) and behavioural problems in individuals with DMD (Angelini, 2007; Counterman et al., 2022).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Van Der Meulen et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Diffusion tensor imaging of the brain
Alexander, A. L., Lee, J. E., Lazar, M., & Field, A. S. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.05.011 · Cited by 2,747 · cited 2×
“37 However, most clinical studies investigating the effects of glucocorticoid overexposure on brain structure have been performed in small, selected populations with chronic glucocorticoid excess due to Cushing disease or systemic glucocorticoid use.”
Halekoh, U., & Højsgaard, S. (2014) · Journal of Statistical Software · doi:10.18637/jss.v059.i09 · Cited by 1,324
The cingulate cortex and limbic systems for emotion, action, and memory
Rolls, E. T. (2019) · Brain Structure and Function · doi:10.1007/s00429-019-01945-2 · Cited by 859
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease
Starkman, M. N., Giordani, B., Gebarski, S. S., Berent, S., Schork, M. A., & Schteingart, D. E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00203-6 · Cited by 455 · cited 1×
“Starkman 1999 [20] 22 patients with active CD Volumetric MRI Sixteen months after TSS, hippocampus volume increased up to 10%, and a smaller increase was observed in caudate volume.”
Prevalence of oral glucocorticoid usage in the United States: a general population perspective
Overman, R. A., Yeh, J., & Deal, C. L. (2013) · Arthritis Care & Research · doi:10.1002/acr.21796 · Cited by 405
Contributions of the insula to cognition and emotion
Gasquoine, P. G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9246-9 · Cited by 400
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Fardet, L., Petersen, I., & Nazareth, I. (2011) · Rheumatology · doi:10.1093/rheumatology/ker017 · Cited by 319
Research works printed but not linked: 52
- Fardet, 2014, Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events, Drugs, 74, 1731, 10.1007/s40265-014-0282-9 · DOI · Paper page
- 10.1136/thoraxjnl-2020-215664 · DOI
- 10.1176/appi.ajp.2014.13091264 · DOI · Paper page
- 10.1210/jc.87.5.1949 · DOI · Paper page
- Hou, 2020, Reversibility of impaired brain structures after transsphenoidal surgery in Cushing's disease: a longitudinal study based on an artificial intelligence-assisted tool, J Neurosurg, 1
- Chen, 2020, Detrimental effects of hypercortisolism on brain structure and related risk factors, Sci Rep, 10, 10.1038/s41598-020-68166-0 · DOI
- 10.1530/EJE-15-0600 · DOI · Paper page
- 10.1016/S0090-3019(99)00197-4 · DOI
- 10.1148/99.2.341 · DOI · Paper page
- 10.1210/jc.2004-2488 · DOI · Paper page
- 10.1016/S0006-3223(02)01750-X · DOI
- Jiang, 2017, Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing's disease, Clin Endocrinol, 87, 367, 10.1111/cen.13381 · DOI
- Bauduin, 2020, Cortical thickness abnormalities in long-term remitted Cushing's disease, Transl Psychiatry, 10, 10.1038/s41398-020-00980-6 · DOI
- 10.1530/EJE-13-0471 · DOI · Paper page
- Toffanin, 2011, Volumetric MRI analysis of hippocampal subregions in Cushing's disease: a model for glucocorticoid neural modulation, Eur Psychiatry, 26, 64, 10.1016/j.eurpsy.2010.09.003 · DOI
- 10.3171/2015.7.FOCUS15257 · DOI
- 10.1016/j.biopsych.2003.09.010 · DOI · Paper page
- 10.1097/JCP.0b013e3181a3e2a7 · DOI
- Brown, 2019, A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus, Neuropsychopharmacology, 44, 2263, 10.1038/s41386-019-0430-8 · DOI
- Nguyen, 2019, The relationship between cumulative exogenous corticosteroid exposure and volumes of hippocampal subfields and surrounding structures, J Clin Psychopharmacol, 39, 653, 10.1097/JCP.0000000000001120 · DOI
- Brown, 2015, Hippocampal volume in healthy controls given 3-day stress doses of hydrocortisone, Neuropsychopharmacology, 40, 1216, 10.1038/npp.2014.307 · DOI
- van der Werff, 2014, Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease, Neuroimage Clin, 4, 659, 10.1016/j.nicl.2014.01.017 · DOI · Paper page
- 10.3174/ajnr.A4322 · DOI
- Jiang, 2017, Altered gray and white matter microstructure in Cushing's disease: a diffusional kurtosis imaging study, Brain Res, 1665, 80, 10.1016/j.brainres.2017.04.007 · DOI
- Pires, 2017, White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study, Pituitary, 20, 340, 10.1007/s11102-017-0793-y · DOI
- Amaya, 2021, Effects of long-term endogenous corticosteroid exposure on brain volume and glial cells in the AdKO mouse, Front Neurosci, 15, 10.3389/fnins.2021.604103 · DOI · Paper page
- 10.1371/journal.pmed.1001779 · DOI · Paper page
- 10.1016/J.NEUROIMAGE.2017.10.034 · DOI · Paper page
- 10.1109/42.906424 · DOI · Paper page
- 10.1016/j.neuroimage.2011.02.046 · DOI · Paper page
- 10.1016/j.neuroimage.2006.02.024 · DOI · Paper page
- Mori S , Wakana S , Van Zijl PC , et al . MRI atlas of human white matter. Elsevier, 2005.
- Dekkers, 2019, Obesity, brain volume, and white matter microstructure at MRI: a cross-sectional UK Biobank study, Radiology, 292, 10.1148/radiol.2019194010 · DOI
- Daley-Yates, 2015, Inhaled corticosteroids: potency, dose equivalence and therapeutic index, Br J Clin Pharmacol, 80, 372, 10.1111/bcp.12637 · DOI · Paper page
- Wickham, 2019, Welcome to the Tidyverse, J Open Source Softw, 4, 1686, 10.21105/joss.01686 · DOI · Paper page
- Zeileis, 2002, Diagnostic checking in regression relationships, R News, 2, 7
- 10.1016/j.biopsych.2007.09.014 · DOI
- 10.1016/j.neuroscience.2015.07.084 · DOI · Paper page
- 10.1016/j.neuropsychologia.2010.06.038 · DOI · Paper page
- 10.1016/j.bbr.2008.11.020 · DOI · Paper page
- 10.1093/brain/awh729 · DOI · Paper page
- Savas, 2020, Systemic and local corticosteroid use is associated with reduced executive cognition, and mood and anxiety disorders, Neuroendocrinology, 110, 282, 10.1159/000501617 · DOI · Paper page
- 10.1002/1098-1136(200009)31:3<219::AID-GLIA30>3.0.CO;2-R · DOI · Paper page
- Miguel-Hidalgo, 2019, Glucocorticoid-induced reductions of myelination and connexin 43 in mixed central nervous system cell cultures are prevented by mifepristone, Neuroscience, 411, 255, 10.1016/j.neuroscience.2019.05.050 · DOI
- 10.1016/j.neulet.2015.03.006 · DOI
- van Olst, 2018, Glucocorticoid-mediated modulation of morphological changes associated with aging in microglia, Aging Cell, 17, 10.1111/acel.12790 · DOI · Paper page
- Freitas, 2016, Agmatine, by improving neuroplasticity markers and inducing NRF2, prevents corticosterone-induced depressive-like behavior in mice, Mol Neurobiol, 53, 3030, 10.1007/s12035-015-9182-6 · DOI
- Machin, 2020, The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis, Clin Rheumatol, 39, 1471, 10.1007/s10067-019-04900-y · DOI
- Pelgrim, 2019, Psychological co-morbidities in COPD: targeting systemic inflammation, a benefit for both?, Eur J Pharmacol, 842, 99, 10.1016/j.ejphar.2018.10.001 · DOI
- Meijer, 2018, Glucocorticoid receptor modulators, Ann Endocrinol, 79, 107, 10.1016/j.ando.2018.03.004 · DOI
- Van Moortel, 2020, Improved glucocorticoid receptor ligands: fantastic beasts, but how to find them?, Front Endocrinol, 11, 10.3389/fendo.2020.559673 · DOI
- 10.1016/j.neuroimage.2011.05.019 · DOI
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- van der Meulen, M., Amaya, J. M., Dekkers, O. M., & Meijer, O. C.
- Affiliations
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2022-08
- Volume
- 12
- Issue
- 8
- Pages
- e062446
- ISSN
- 2044-6055
- Cited by
- 41
- References
- 18
- Language
- en
- Funders
- Cancer Research UK (N/A)
- Department of Health (N/A)
- Scottish Government (N/A)
- Northwest Regional Development Agency (N/A)
- Leids Universitair Medisch Centrum (N/A)
- CONACyT (440584)
- Welsh Government (N/A)
- British Heart Foundation (N/A)
- Medical Research Council (N/A)
- Diabetes UK (N/A)
- Wellcome Trust (N/A)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank. https://app.cochat.ai/papers/10.1136/bmjopen-2022-062446
- The paper
- van der Meulen, M., Amaya, J. M., Dekkers, O. M., & Meijer, O. C. (2022). Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank. BMJ Open. https://doi.org/10.1136/bmjopen-2022-062446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.